Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

JRI vs JRS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

JRS Captures Overall Composite Edge (38.1 SELL vs 39.1 SELL), While JRI Leads 1–0 on Growth & Valuation Pillars

JRS Overall Winner 6-Pillar Tally: JRI 1 – 0 JRS (5 Tie) Matrix Metrics: JRI 2 – 2 JRS

As of Nov 16, 2026, Nuveen Real Estate Income Fund (JRS) captures the overall head-to-head institutional edge over Nuveen Real Asset Income And Growth Fund (JRI) on higher Unified Composite conviction (38.1/100 SELL vs. 39.1/100 SELL) after splitting the core matrix 2–2 (led by composite factor balance), while JRI wins 1–0 across the 6-pillar growth and valuation breakdown. JRI trades at $11.09 (N/M Forward P/E, N/A operating margin) versus JRS at $7.59 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While JRI currently prints a higher short-term Unified Composite Score (39.1/100 SELL vs. JRS 38.1/100 SELL), JRS captures the overall institutional head-to-head verdict (2–2 matrix metrics and 0–1 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
  • Defensive Composite Rating Caution: Although JRS compares more favorably head-to-head, both JRI (39.1/100 SELL) and JRS (38.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: JRI is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 46.0); meanwhile JRS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 52.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About JRI vs JRS
JRI NYSE
Nuveen Real Asset Income And Growth Fund
Institutional Equity
$11.09
-1.77% 1D
Market Cap $392.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.51β · 22% Vol
Unified Composite Score
39.1 / 100 SELL
Tech 47.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -4.1%) with fading momentum, RSI 46
RSI-14: 46.0 · SMA20: $11.22 · SMA50: $11.15
JRS NYSE Head-to-Head Winner
Nuveen Real Estate Income Fund
Institutional Equity
$7.59
-0.78% 1D
Market Cap $236.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.48β · 19% Vol
Unified Composite Score
38.1 / 100 SELL
Tech 48.0 Fund 47.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.1 · SMA20: $7.55 · SMA50: $7.53

6-Pillar Scorecard Institutional Category Breakdown (JRI 1 – 0 JRS)

Columns: Metric · JRI · JRS
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale JRI
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap $392.9M $236.9M
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: JRI (2) vs JRS (2)
Institutional Metric JRI JRS Criterion Row Edge
Market Capitalization
Scale
$392.9M $236.9M Larger Scale JRI
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
22% ($10–$14) 27% ($7–$9) Stronger Trend JRS
Beta / 30D Volatility
Risk Regime
0.51β · 22% Vol 0.48β · 19% Vol Lower Realized Risk JRS
Unified Institutional Score
Composite Signal
39.1 / 100 (SELL) 38.1 / 100 (SELL) Higher Composite JRI
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon JRI +0.62 pp
JRI: +5.02% · JRS: +4.4%
3M Horizon JRS +0.67 pp
JRI: -10.85% · JRS: -10.18%
6M Horizon JRS +7.32 pp
JRI: -12.68% · JRS: -5.36%
1Y Horizon JRS +15.05 pp
JRI: -19.46% · JRS: -4.41%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on JRI vs JRS. Trailing 12-month operating profitability (JRI N/A vs JRS N/A) and valuation multiples (JRI N/M vs JRS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

JRI ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
JRS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
JRI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact JRI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
JRS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact JRS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
JRI Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $392.9M market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
JRS Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $236.9M market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ JRI vs JRS Key Questions & Quantitative Answers

As of Nov 16, 2026, Nuveen Real Estate Income Fund (JRS) captures the overall head-to-head institutional edge over Nuveen Real Asset Income And Growth Fund (JRI) on higher Unified Composite conviction (38.1/100 SELL vs. 39.1/100 SELL) after splitting the core matrix 2–2 (led by composite factor balance), while JRI wins 1–0 across the 6-pillar growth and valuation breakdown. JRI trades at $11.09 (N/M Forward P/E, N/A operating margin) versus JRS at $7.59 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While JRI currently prints a higher short-term Unified Composite Score (39.1/100 SELL vs. JRS 38.1/100 SELL), JRS captures the overall institutional head-to-head verdict (2–2 matrix metrics and 0–1 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Defensive Composite Rating Caution: Although JRS compares more favorably head-to-head, both JRI (39.1/100 SELL) and JRS (38.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: JRI is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 46.0); meanwhile JRS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 52.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

JRI leads the Growth & Scale pillar: JRI posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with JRS at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, JRI generates N/A in USD-normalized revenue versus N/A for JRS. In operating R&D and SG&A reinvestment, JRI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for JRS.

JRI and JRS trade at balanced relative valuation multiples. JRI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas JRS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against JRI (N/A ROE) versus JRS (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, JRI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.51β · 22% Vol realized risk). By comparison, JRS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.48β · 19% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.